Table 1.
Clinical characteristics of study population
| Sex | N (% of total 160) | |
|---|---|---|
| Male | 61 (38 %) | |
| Female | 99 (62 %) | |
| Age (years) | ||
| Median | 55 (Range: 19–89) | |
| Follow-up (months) | ||
| Median | 17 (Range: 0–118) | |
| Survival (months) | ||
| Median | 31 (Range: 0–118) | |
| ENS@T Stage at diagnosis | Survival median | |
| Unknown | 2 (1 %) | |
| I | 9 (6 %) | * |
| II | 58 (36 %) | 62 Months |
| III | 41 (26 %) | 32 Months |
| IV | 50 (31 %) | 7 Months |
| Metastases | ||
| None | 43 (27 %) | |
| Synchronous metastases | 84 (53 %) | |
| Metachronous metastases | 33 (21 %) | |
| At the time of first metastases | Any time during follow-up | |
| Liver | 43 (27 %) | 65 (41 %) |
| Lung | 58 (36 %) | 79 (49 %) |
| Bone | 8 (5 %) | 21 (13 %) |
| Lymph nodes under diaphragm | 32 (20 %) | 52 (33 %) |
| Lymph nodes above diaphragm | 11 (7 %) | 27 (17 %) |
| Other location | 16 (10 %) | 47 (29 %) |
*Could not be calculated